Ginkgo Bioworks Stock Drops 20% After Short Sellers Call Company A 'Colossal Scam'

Shares of synthetic biology company Ginkgo Bioworks Holdings Inc DNA traded lower by more than 20% on Wednesday.

What Happened? In a new report, Citron Research editor Andrew Left said called Ginkgo "a scheme” and said the company’s recent $24 billion valuation is absurd given it raised capital in 2020 at roughly a $5 billion valuation.

Left's comments come after Scorpion Capital called Ginkgo a “colossal scam” on Wednesday and disclosed a short position in the stock.

Related: What To Know About Ginkgo Bioworks SPAC Deal: 'Cell Programming Has The Potential To Impact Every Physical Goods Industry'

Why It’s Important: Left reiterated several red flags that Scorpion pointed out concerning Ginkgo, including an overly promotion CEO, minimal synthetic biology revenue and no proprietary technology or tangible products in the market.

“We’ve too checked with DNA former employees and we don’t think Scorpion is missing anything here,” Left said in the report. “We will let others set targets…Citron just needed to add commentary whenever we see a CEO talking about bringing back dinosaurs.”

Ginkgo Bioworks' high-profile investors include Bill Gates and Ark Invest CEO Cathie Wood, who has large holdings of the stock in both her ARK Genomic Revolution ETF ARKG and her popular ARK Innovation ETF ARKK.

Left has taken a lot of heat from critics since taking a short position and setting a $20 price target for GameStop Corp. GME in January, a move that angered Reddit’s WallStreetBets community.

Following the initial surge in GameStop and alleged threats against his family from GameStop traders, the longtime activist short-seller said he will no longer be issuing short reports.

Instead of recommending a short position in Ginkgo, Left pointed out that investors should find a way to invest in privately-held hedge fund Viking Global, which started buying shares of Ginkgo in the private market at a $200 million valuation.

“And now it is your turn to buy at $24 billion…say what???” Left said.

The company was not immediately available for comment.

Benzinga’s Take: Left always takes a lot of criticism for his missed short calls, and he has been wrong up to this point on GameStop. However, Citron’s annual shareholder letter revealed its average exposure in 2020 was 20% long, and the fund generated a net return of 155% on the year.

Posted In: Andrew LeftBill GatesCathie WoodCitron ResearchScorpion CapitalViking GlobalAnalyst ColorBiotechShort SellersShort IdeasTop StoriesAnalyst RatingsTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.